作者
Dara A Lehman, Jared M Baeten, Connor O McCoy, Julie F Weis, Dylan Peterson, Gerald Mbara, Deborah Donnell, Katherine K Thomas, Craig W Hendrix, Mark A Marzinke, Lisa Frenkel, Patrick Ndase, Nelly R Mugo, Connie Celum, Julie Overbaugh, Frederick A Matsen, Partners PrEP Study Team, Connie Celum, Jared M Baeten, Deborah Donnell, Robert W Coombs, Lisa Frenkel, Craig W Hendrix, Mark A Marzinke, Jairam Lingappa, M Juliana McElrath, Kenneth Fife, Edwin Were, Elioda Tumwesigye, Patrick Ndase, Elly Katabira, Elly Katabira, Allan Ronald, Elizabeth Bukusi, Craig Cohen, Jonathan Wangisi, James Campbell, Jordan Tappero, James Kiarie, Carey Farquhar, Grace John-Stewart, Nelly Rwamba Mugo, James Campbell, Jordan Tappero, Jonathan Wangisi
发表日期
2015/4/15
期刊
The Journal of infectious diseases
卷号
211
期号
8
页码范围
1211-1218
出版商
Oxford University Press
简介
Background. Preexposure prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodeficiency virus (HIV) acquisition. Understanding the risk of antiretroviral resistance selected by PrEP during breakthrough infections is important because of the risk of treatment failure during subsequent antiretroviral use.
Methods. Within the largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested for HIV with resistance mutations associated with FTC (K65R and M184IV) and TDF (K65R and K70E), using 454 sequencing.
Results. Of 121 HIV seroconverters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo. Plasma drug levels in 26 individuals indicated PrEP use during or after HIV acquisition, of which 5 had virus with resistance …
学术搜索中的文章
DA Lehman, JM Baeten, CO McCoy, JF Weis… - The Journal of infectious diseases, 2015